NEW YORK (GenomeWeb News) – BG Medicine today reported third quarter revenues of $695,000, down 31 percent from $1 million in the third quarter of 2013.

The decline was due almost entirely to a drop in product revenues from sales of the company's BGM Galectin-3 test, which fell to $695,000 in the quarter, down 31 percent percent from $1 million in Q3 2013. BG reported no revenues from its service business for the most recent quarter compared to $23,000 a year ago.

The company's revenues fell short of the Wall Street consensus estimate of $800,000.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.